Dermatol Ther:局部应用依克多因可有效治疗与皮肤屏障受损有关的皮炎

2022-01-26 MedSci原创 MedSci原创

炎症性皮肤病患者饱受皮肤不适(如干燥、发红和瘙痒)的痛苦。润肤剂被用于皮炎的基础治疗,以恢复天然皮肤屏障和缓解症状。

炎症性皮炎患者常会出现干燥、发红和瘙痒等症状。润肤剂常用作炎症性皮炎的基础治疗,以恢复天然皮肤屏障并缓解炎症症状。近日,发表于Dermatol Ther (Heidelb)的一项系统回顾评估了含有麦考酚胺的外用制剂治疗以皮肤屏障受损为特征的炎症性皮炎的疗效和安全性。

研究人员检索了PubMed、Cochrane图书馆和Microsoft Academic中2021年10月以前收录的相关研究。纳入标准是用于(辅助)治疗炎症性皮肤病的含外激素的外用制剂(乳膏、润肤剂)。

结果,研究人员共筛选出230篇符合条件的参考文献,其中6篇被选入综述(5篇关于特应性皮炎的研究和1篇关于预防和处理维甲酸酯皮炎的研究)。分析结果显示,应用含有5.5-7.0%的外用制剂可有效改善特应性皮炎患者的皮肤干燥,并由此改善患者的瘙痒和皮炎特异性评分。尤其是是婴儿和儿童患者,这些这些外用制剂4周时显示出良好的耐受性。

在研究中,如果将依克多因作为一种辅助治疗,那么麦考酚胺的使用与药物治疗的需求减少有关,并且还能提高局部皮质类固醇治疗的有效性。在接受异维A酸治疗的患者中,依克多因在减少维甲酸酯皮炎或改善症状方面一样有效。

综上所述,该究结果表明,依克多因是一种有效的天然物质,具有良好的耐受性和安全性,是一种有益的替代物,可作为基础治疗,也可提高包括婴儿和儿童在内的炎症性皮肤病患者药物治疗方案的疗效。

原始出处:

Marion Kauth, Olga V Trusova. Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review. Dermatol Ther (Heidelb). 2022 Jan 17. doi: 10.1007/s13555-021-00676-9.  

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1688713, encodeId=90241688e13f5, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Thu Mar 31 19:21:20 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189436, encodeId=ce6f11894365c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49d86150402, createdName=ms5000001035087752, createdTime=Mon Jan 31 11:26:35 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188642, encodeId=a8bf11886428e, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Thu Jan 27 18:38:34 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188517, encodeId=cb37118851ea3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1175602159, createdName=ms9000000762087499, createdTime=Thu Jan 27 08:14:54 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188361, encodeId=8cfa1188361dc, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Wed Jan 26 18:01:24 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406153, encodeId=2a581406153a9, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619631, encodeId=5e2a16196312a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1688713, encodeId=90241688e13f5, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Thu Mar 31 19:21:20 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189436, encodeId=ce6f11894365c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49d86150402, createdName=ms5000001035087752, createdTime=Mon Jan 31 11:26:35 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188642, encodeId=a8bf11886428e, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Thu Jan 27 18:38:34 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188517, encodeId=cb37118851ea3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1175602159, createdName=ms9000000762087499, createdTime=Thu Jan 27 08:14:54 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188361, encodeId=8cfa1188361dc, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Wed Jan 26 18:01:24 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406153, encodeId=2a581406153a9, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619631, encodeId=5e2a16196312a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-31 ms5000001035087752

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1688713, encodeId=90241688e13f5, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Thu Mar 31 19:21:20 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189436, encodeId=ce6f11894365c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49d86150402, createdName=ms5000001035087752, createdTime=Mon Jan 31 11:26:35 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188642, encodeId=a8bf11886428e, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Thu Jan 27 18:38:34 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188517, encodeId=cb37118851ea3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1175602159, createdName=ms9000000762087499, createdTime=Thu Jan 27 08:14:54 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188361, encodeId=8cfa1188361dc, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Wed Jan 26 18:01:24 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406153, encodeId=2a581406153a9, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619631, encodeId=5e2a16196312a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-27 ms1000000413528422

    好好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1688713, encodeId=90241688e13f5, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Thu Mar 31 19:21:20 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189436, encodeId=ce6f11894365c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49d86150402, createdName=ms5000001035087752, createdTime=Mon Jan 31 11:26:35 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188642, encodeId=a8bf11886428e, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Thu Jan 27 18:38:34 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188517, encodeId=cb37118851ea3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1175602159, createdName=ms9000000762087499, createdTime=Thu Jan 27 08:14:54 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188361, encodeId=8cfa1188361dc, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Wed Jan 26 18:01:24 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406153, encodeId=2a581406153a9, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619631, encodeId=5e2a16196312a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-27 ms9000000762087499

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1688713, encodeId=90241688e13f5, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Thu Mar 31 19:21:20 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189436, encodeId=ce6f11894365c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49d86150402, createdName=ms5000001035087752, createdTime=Mon Jan 31 11:26:35 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188642, encodeId=a8bf11886428e, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Thu Jan 27 18:38:34 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188517, encodeId=cb37118851ea3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1175602159, createdName=ms9000000762087499, createdTime=Thu Jan 27 08:14:54 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188361, encodeId=8cfa1188361dc, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Wed Jan 26 18:01:24 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406153, encodeId=2a581406153a9, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619631, encodeId=5e2a16196312a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-26 ms4000001513304915

    学习#学习#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1688713, encodeId=90241688e13f5, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Thu Mar 31 19:21:20 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189436, encodeId=ce6f11894365c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49d86150402, createdName=ms5000001035087752, createdTime=Mon Jan 31 11:26:35 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188642, encodeId=a8bf11886428e, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Thu Jan 27 18:38:34 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188517, encodeId=cb37118851ea3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1175602159, createdName=ms9000000762087499, createdTime=Thu Jan 27 08:14:54 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188361, encodeId=8cfa1188361dc, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Wed Jan 26 18:01:24 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406153, encodeId=2a581406153a9, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619631, encodeId=5e2a16196312a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-25 chg122
  7. [GetPortalCommentsPageByObjectIdResponse(id=1688713, encodeId=90241688e13f5, content=<a href='/topic/show?id=df07e202459' target=_blank style='color:#2F92EE;'>#皮肤屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72024, encryptionId=df07e202459, topicName=皮肤屏障)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f1528615202, createdName=644982816_68283330, createdTime=Thu Mar 31 19:21:20 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189436, encodeId=ce6f11894365c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49d86150402, createdName=ms5000001035087752, createdTime=Mon Jan 31 11:26:35 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188642, encodeId=a8bf11886428e, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6d5619254, createdName=ms1000000413528422, createdTime=Thu Jan 27 18:38:34 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188517, encodeId=cb37118851ea3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1175602159, createdName=ms9000000762087499, createdTime=Thu Jan 27 08:14:54 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188361, encodeId=8cfa1188361dc, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Wed Jan 26 18:01:24 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406153, encodeId=2a581406153a9, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619631, encodeId=5e2a16196312a, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Jan 25 08:21:20 CST 2022, time=2022-01-25, status=1, ipAttribution=)]

相关资讯

超350万人12年随访研究:噪音烦人还超伤身!明确升高2型糖尿病风险!

Environ Health Perspect.:丹麦一项全国队列研究:长期暴露于交通噪音与2型糖尿病风险

Journal of Epidemiology & Community Health:扎心!孤独或分手增加男性炎症水平,增加死亡风险

众所周知,孤独不利于心理健康,但你可能不知道,孤独对身体健康也会造成很大危害。伴侣关系破裂,通常伴随着可能长时间的独居,与身体和心理健康状况不佳、免疫力下降和死亡的风险增加有关。

接着吃来接着摇!好吃好玩还低卡的Ta,还能调血脂血糖抗氧化!

Nutrition & Metabolism:食用红海藻石花菜(Campylaephora hypnaeoides J. Agardh)通过抑制氧化应激和炎症反应减轻小鼠肥胖和相关代谢紊乱

JCEM:伴有和不伴有2型糖尿病的COVID-19住院患者炎症与死亡率的关系

该研究的结果表明COVID19患者死亡率与血清中先天炎性细胞因子IL-6和炎性趋化因子IL-8和IP10的水平升高相关。

EULAR :重视风湿性免疫相关不良事件

在接受检查点抑制剂 (CPI) 治疗的癌症患者中,约有 10% 观察到风湿性和肌肉骨骼免疫相关不良事件 (irAE)。

JAAD:雄激素性脱发真的是非炎症性脱发吗?

雄激素性脱发(AGA)可能影响多达50%的成年人。虽然AGA被归类为非炎症性、非瘢痕性脱发,但炎症的组织学证据早已得到认可。本文进一步研究了雄激素性脱发的炎症性反应。